Bristol-Myers Squibb’s Opdivo approved in new lymphoma indication

Bristol-Myers Squibb has announced that its drug Opdivo has been approved in a new classical Hodgkin lymphoma indication by the European Commission.

The drug has been ratified for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

It becomes the first and only PD-1 inhibitor approved for a haematologic malignancy in the EU, with this decision marking the sixth EU approval for Opdivo in four distinct cancer types in less than two years.

The latest approval was based on clinical data supporting the drug's strong overall response rate, as demonstrated by the results of an integrated analysis of two trials, CheckMate -205 and CheckMate -039.

Emmanuel Blin, senior vice-president and chief strategy officer at Bristol-Myers Squibb, said: "We're incredibly proud of this approval for Opdivo and what it means for adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin."

This also marks Bristol-Myers Squibb's second immuno-oncology agent approved for blood cancer treatment in the EU within six months.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.